Literature DB >> 8480541

Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role.

C Agen1, R Danesi, C Blandizzi, M Costa, B Stacchini, P Favini, M Del Tacca.   

Abstract

The antiinflammatory activity of a new 14-membered macrolide antibiotic, roxithromycin, was evaluated in various rat models including carrageenan- and poly-L-arginine-induced hind-paw oedema, croton oil inflamed ear assay and polyester sponge granuloma. When administered orally to animals, roxithromycin displayed an atypical profile in the assays utilized, including: (1) marked antioedema activity similar to that of indomethacin in poly-L-arginine assay, (2) significant inhibition of lambda-carrageenan hind-paw oedema and croton-oil-induced inflammation in the ear, although indomethacin was more effective, and (3) failure to reduce the development of granuloma induced by implanted polyester sponges, while indomethacin significantly reduced the chronic inflammatory reaction. Based on these results, it is concluded that roxithromycin is active in reducing the acute inflammatory reaction in rat models through mechanisms different from conventional nonsteroidal antiinflammatory agents such as indomethacin. Therefore, roxithromycin may have a favorable impact on skin inflammatory reactions accompanying microbial infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480541     DOI: 10.1007/bf02027218

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  26 in total

1.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

Authors:  M T Labro; J el Benna; C Babin-Chevaye
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

2.  Inhibitory effect of indomethacin farnesil, a novel antiinflammatory prodrug, on carrageenin-induced inflammation in rats.

Authors:  S Kumakura; M Mishima; S Kobayashi; H Shirota; S Abe; K Yamada; S Tsurufuji
Journal:  Agents Actions       Date:  1990-03

3.  Clinical evaluation of roxithromycin in odontogenic orofacial infections.

Authors:  J Sasaki
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

4.  In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Roxithromycin in skin and soft tissue infections.

Authors:  P Agache; P Amblard; G Moulin; H Barrière; L Texier; C Beylot; H Bergoend
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

7.  Cutaneously applied erythromycin base reduces various types of inflammatory reactions in mouse ear.

Authors:  J P Tarayre; M Aliaga; M Barbara; G Villanova; R Ballester; J Tisne-Versailles; J P Couzinier
Journal:  Int J Tissue React       Date:  1987

8.  Erythromycin induces migrating motor complex in human gastrointestinal tract.

Authors:  T Tomomasa; T Kuroume; H Arai; K Wakabayashi; Z Itoh
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

9.  Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein.

Authors:  L J Ignarro; M E Gold; G M Buga; R E Byrns; K S Wood; G Chaudhuri; G Frank
Journal:  Circ Res       Date:  1989-02       Impact factor: 17.367

10.  Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites.

Authors:  M Simionescu; N Simionescu; J E Silbert; G E Palade
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

View more
  16 in total

Review 1.  [Angiology update].

Authors:  C Ranke; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-05-15

Review 2.  The anti-inflammatory effects of macrolides.

Authors:  D Wales; M Woodhead
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Anti-inflammatory effects of ivermectin in mouse model of allergic asthma.

Authors:  Shuhan Yan; Xinxin Ci; Na Chen; Chi Chen; Xiangchao Li; Xiao Chu; Jianhua Li; Xuming Deng
Journal:  Inflamm Res       Date:  2011-01-29       Impact factor: 4.575

Review 4.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

5.  Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.

Authors:  H Levert; B Gressier; I Moutard; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

Review 6.  Macrolide antibiotics.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

7.  Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells.

Authors:  J Yatsunami; Y Fukuno; M Nagata; M Tominaga; S Aoki; N Tsuruta; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

8.  Porphyromonas gingivalis lipopolysaccharide-stimulated bone resorption via CD14 is inhibited by broad-spectrum antibiotics.

Authors:  Y Miyata; H Takeda; S Kitano; S Hanazawa
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

9.  Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.

Authors:  J Yatsunami; N Tsuruta; Y Fukuno; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.